Consultancy
4 Ways De-Risking Maximizes Compound Value
Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by conducting early in...
Filing an IND and Beyond: Development of CTD Section 2.6.4, Pharmacokinetics Written Summary
Guide to When & Why to Evaluate ADME/DMPK & Drug-Drug Interactions Available
In Safety first: Assessing drugs early can preclude regulatory and health issues, a new ebook developed by a collaboration with...
Four Ways CROs Drive Innovation for Improved In Vitro Drug Metabolism and Pharmacokinetics (DMPK) Studies
Agility and focused growth allow drug developers to outsource expertise and benefit the industry at-large by fostering innovation. Panelists at the 2021 Annual DMDG Meeting…
DDI & Drug Repurposing Article featured in Drug Discovery World (DDW) Spring Edition 2021
Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success.…
Interview with Outsourcing Pharma: Repurposing existing drugs accelerates discovery
“Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an...
Important DDI Considerations for Repurposing Drugs to Treat COVID-19
“Given the rapid spread of COVID-19 and its relatively high mortality, filling the gap for coronavirus-specific drugs is urgent. […]...
Meet the Scientist: Pallavi Limaye
We have welcomed a new consultant to the team! Dr. Pallavi Limaye now serves as a Director in the Scientific...
In Vitro Evaluation of Drug-Drug Interaction (DDI) Potential
In its most recent in vitro drug interaction guidance update, the US Food and Drug Administration (FDA) emphasized harmony with the...
Four ways to optimize preclinical in vitro data to mitigate risk of late-stage clinical failure
1. Collect high-quality data to make informed, confident go/no go decisions for moving your drug candidate forward If you need...
How can in vitro and in vivo studies help me understand my drug’s clearance?
Systemic clearance, denoting how much drug is cleared from a volume of blood per unit of time, is of critical...
I Have My Data… Now What?
As a drug moves through the development pipeline, it undergoes a rigorous battery of safety assessments to prove it will...
The FDA has requested follow-up data… how do I fill in the gaps?
Because each new drug is unique in characteristics, such as chemical structure, mechanism of action, and physicochemical properties, there can...
Consultancy Expansion
We are proud to house some of the brightest minds in this field who have seen “the weird stuff” when...
New VP of Scientific Operations and VP of Scientific Consulting
XenoTech has appointed Joanna Barbara, Ph.D., as Vice President of Scientific Operations and Brian Ogilvie, Ph.D., as Vice President of Scientific...